| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 35 | 14,070 |
| HNI / NII | 72 | 2520 | 10,13,040 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 3,62,97,998 (48.20%) | — | ₹145,917.95 Cr |
| NII / HNI (Total) | — | 1,08,89,400 (14.46%) | — | ₹43,775.39 Cr |
| Retail Investors | — | 2,54,08,599 (33.74%) | — | ₹102,142.57 Cr |
| Employee | — | 15,79,399 (2.10%) | — | ₹634.92 Cr |
| Total ** | — | 7,53,04,970 (100.00%) | — | ₹3,027,259.80 Cr |
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 837.94 | 1376.45 | 1031.49 |
| PAT | 39.56 | 95.05 | 103.23 |
| EBITDA | — | — | — |
| Net Worth | 1502.67 | 1337.68 | 627.83 |
| Total Assets | 3393.41 | 2752.82 | 1825.17 |
| Reserves | 1509.11 | 1365.86 | 652.63 |
| Borrowings | 373.68 | 387.79 | 356.18 |
Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.
As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.
The Services provided by the company are:-
Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;
Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).
Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.
As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).
As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.
Competitive Strength